3 Articles
3 Articles
Will Makary's FDA voucher program survive?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Even though RevMed’s experimental pancreatic cancer drug, daraxonrasib, hasn’t yet achieved approval, it is available through an expanded access program. But that doesn’t mean getting it is easy. Also, the FDA’s voucher program spearheaded by erstwhile chief Marty Makary could be in for a makeover.Continue to STAT+ to read …
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center3Last Updated100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium


